Oregontherapeutics
OregonTherapeutics is developing XCE853 : Disruptive targeted therapy “First in class” & “Best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action : Inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into clinical trial (phase 1) for the treatment of cancer within 2 years. Based on the scientific rationale, the priority indication is advanced pancreatic cancer. Potential additional indications are ovarian, livers, and head & neck cancers.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
1
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Oregontherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Oregontherapeutics
2 distinct titles indexed · top 2 shown.
- 1ceo
- 1principal chief executive officer
Sign up to unlock all 2 contacts at Oregontherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Oregontherapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.